Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding phase Ib/IIa trial of BNT164 tuberculosis vaccines in BCG-vaccinated HIV-negative adults
PACTR202505818080160Phase 2Unknown
- Sponsor
- BioNTech SE
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial in Tuberculosis (TB) comparing BNT164a1, BNT164b1 and Placebo (3 arms). Status: unknown.
02
Drugs
BNT164a1BNT164b1
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202505818080160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505818080160.